Veeva Systems (VEEV) is set to join the S&P 500 Index on May 7, 2026, after a share price surge that has drawn fresh attention to its life sciences software business and AI driven product push.

The S&P 500 news comes after a mixed period for investors, with a 1 day share price return of 10.02% and a year to date share price return decline of 21.82%, while the 1 year total shareholder return decline of 27.44% points to weaker longer term sentiment despite recent momentum.

If Veeva’s AI and index inclusion story has your attention, it could be a good moment to scan other healthcare focused AI names using our 33 healthcare AI stocks

With Veeva trading at a discount to its analyst price target and an intrinsic value estimate, yet already enjoying an index driven bounce, are you looking at a genuine mispricing here, or is the market already baking in future growth?

Most Popular Narrative: 35.1% Undervalued

Against Veeva Systems' last close of $171.60, the most followed narrative points to a fair value of $264.46, implying a sizable valuation gap that rests on specific growth and profitability assumptions.

The resolution of the long-standing dispute with IQVIA removes critical data interoperability barriers, enabling Veeva to fully integrate industry-leading datasets into its Commercial Cloud. This integration should materially expand its addressable market, improve product adoption across multiple commercial applications, and accelerate top-line revenue growth over the next several years. Veeva's rapid progress embedding advanced AI agents directly within its Vault platform, across both R&D and Commercial suites, positions it as a workflow and automation partner amid the rising complexity of personalized medicine, genomics, and data-driven trials. This positioning has the potential to support higher pricing power, platform stickiness, and net margin expansion in the medium to long term.

Curious what kind of revenue runway, margin profile, and future earnings multiple are baked into that fair value, and how an 8.25% discount rate ties it all together.

Result: Fair Value of $264.46 (UNDERVALUED)

However, that story can crack if CRM competition eats into renewals or if heavy AI and cloud investment fails to translate into the earnings analysts are modeling.

Another Way To Look At Veeva’s Valuation

The story above leans on a fair value of $264.46, yet the SWS DCF model points to a future cash flow value of $271.03, with Veeva trading around $171.60. Both views frame the shares as undervalued. The key question is how much confidence investors should place in long range cash flow forecasts.

Next Steps

With sentiment running in different directions throughout this article, it makes sense to move quickly, review the numbers directly, and weight the 3 key rewards

Looking for more investment ideas?

If you stop with just one stock, you risk missing other opportunities that fit your goals, risk comfort, and income needs, so consider widening your search with a few targeted screens.

• Focus on quality at a reasonable price by checking companies highlighted in our 50 high quality undervalued stocks.
• Strengthen your emphasis on financial resilience by screening for businesses in the solid balance sheet and fundamentals stocks screener (44 results).
• Expand your watchlist with income focused opportunities using the 13 dividend fortresses.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.